Maturity-onset diabetes of the young by Fajans, Stefan S. et al.
Pergamon 
0024-3205(94)00138-3 
Life Sciences, Vol. 55, No. 6, pp. 413-422, 1994 
Copyright © 1994 Elsevier Science Ltd 
Printed in the USA. All rights reserved 
0024-3205/94 $6.00 + .00 
MINIREVIEW 
MATURITY-ONSET DIABETES OF THE YOUNG 
Stefan S. Fajans*, Graeme I. Bell**, Donald W. Bowden***, Jeffrey B. Halter*t, Kenneth S. 
Polonskytt 
*Department of Internal Medicine, University of Michigan Medical Center and the 1"Department 
of Veterans Affairs Medical Center, Ann Arbor, MI, **The Howard Hughes Medical Institute, 
University of Chicago, Chicago, IL, ***Department of Biochemistry, Bowman Gray School of 
Medicine, Wake Forest University, Winston-Salem, NC and ttDepartment of Medicine, 
University of Chicago, IL 
(Received in final form May 25, 1994) 
Summary. 
Maturity-onset diabetes of the young (MODY) is a subtype of noninsulin 
dependent diabetes mellitus (NIDDM). It is characterized by an early age of 
onset and autosomal dominant mode of inheritance. These features and the 
availability of large multigenerational pedigrees make MODY useful for genetic 
studies of diabetes. In the large, 5-generational RW pedigree, MODY is tightly 
linked to genetic markers on chromosome 20q. Affected subjects in this family 
show abnormalities of carbohydrate metabolism varying from impaired glucose 
tolerance (IGT) to severe diabetes. Approximately 30% of diabetic subjects 
become insulin requiring and vascular complications occur. MODY is also 
linked to the glucokinase gene on chromosome 7p and many different mutations 
associated with MODY have been identified in this gene. MODY due to 
mutations in the glucokinase gene is a relatively mild form of diabetes with mild 
fasting hyperglycemia and IGT in the majority. It is rarely insulin requiring and 
rarely has vascular complications. Clinical studies indicate that the genetic or 
primary defect in MODY is characterized by deranged and deficient insulin 
secretion and not by insulin resistance and that there are quantitative and 
qualitative differences in insulin secretory defects which differentiate subjects 
with MODY due to glucokinase mutations from those with mutations in the gene 
on chromosome 20q. These differences correlate with the severity of diabetes 
between these two genetic forms of MODY. 
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The purpose of this minireview is to summarize our expanding knowledge of the phenotypic 
expression, natural history, molecular genetics and pathogenesis of maturity-onset diabetes of 
the young, abbreviated as MODY. MODY is a relatively uncommon subtype of noninsulin- 
dependent diabetes mellitus (NIDDM). It is generally recognized that the latter is a 
heterogeneous disorder (1). Recent investigations have indicated that MODY is phenotypically 
and genetically heterogeneous as well. It is a valuable model for the study of the molecular 
genetics and pathogeneses of NIDDM (2). 
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414 Maturity-onset Diabetes of the Young Vol. 55, No. 6, 1994 
Definition, phenotypic expression and natural historv 
MODY is defined as NIDDM characterized by an early age of onset and autosomal dominant 
mode of inheritance (2-4). The history of the use of this term and its abbreviation have been 
reviewed previously (3,4). More recently, it has also been referred to as early-onset NIDDM 
(5,6). When MODY is suspected and family members are examined biochemically, a diagnosis 
of diabetes can be made almost invariably under the age of 25 years, frequently between the ages 
of 9-13 years, and in some families at an even earlier age. Because of autosomal dominant 
inheritance and early age of onset it is possible to collect large multigenerational pedigrees with 
MODY, a unique feature of this subtype of NIDDM. When MODY pedigrees are studied 
prospectively, much can be learned about the phenotypic expression and natural history of this 
type of diabetes. 
The RW Pedigree, consisting of more than 360 presently identified members including 72 
known subjects with diabetes distributed over 5 generations, has been studied and followed 
prospectively by one of us (SSF) since 1958. The propositus, 11-5 (W branch), offspring of 1-3, 
had diabetes diagnosed at the age of 41 years (Fig. IA). He was blind from diabetic retinopathy 
at the age of 61 years and had an amputation for peripheral vascular disease. He had five 
brothers, four of whom had diabetes and one who did not. Macrovascular disease including 
myocardial infarctions and peripheral vascular disease with gangrene and amputations, as well 
as microvascular disease including retinopathy and blindness are complications resulting from 
MODY in the RW pedigree (Fig. 1). In addition to these, there is also evidence of neuropathy. 
In 1958, the eleven nonobese, apparently healthy and asymptomatic offspring of 11-5 were 
recruited for routine blood glucose testing. Seven of the eleven were found to have abnormal 
glucose metabolism (3). The older three had fasting hyperglycemia (mean 257 mg/dl), three 
others had diabetic glucose tolerance tests without diagnostic fasting hyperglycemia, and one 
had impaired glucose tolerance (IGT). With follow-up, all have developed fasting 
hyperglycemia. Two have been treated with insulin because of eventual unresponsiveness to 
sulfonylurea drugs, four have been treated successfully with sulfonylurea drugs up to the 
present, and one is using diet alone, although sulfonylurea therapy is indicated because he has 
recently developed fasting hyperglycemia. Subsequently, by routine blood glucose testing 
diabetes was diagnosed in 10 of the 20 members of generation IV who are offspring of diabetic 
subjects of generation III, and up to the present time in four members of generation V. None of 
them are obese. Ages of diagnosis were 9-14 years in twelve of these patients with diabetes. 
Patient IV-144 has typical IDDM. 
Among offspring of 11-2, three of the 5 diabetic members (III-3, III-4, III-8) have MODY 
segregating in generations III-V (Fig. 1B). Two of the 5 (111-2, 111-9) are obese, are 
hyperinsulinemic, while MODY subjects are generally hypoinsulinernic (see below), and were 
diagnosed with diabetes at age 48 years in one (111-2) and in the other at age 61 (111-9) by 
prospective testing. Of the twelve offspring of II-3, six have NIDDM. In none was the 
diagnosis made before the age of 43 years, although in none was blood glucose testing 
performed at an earlier age. Moreover, none of the 44 offspring of these six diabetic patients 
who have been tested have diabetes at the present time. Similarly, none of the four offspring of 
diabetic II-6 has diabetes, nor do any of their 15 offspring who have been tested. It appears that 
offspring of II-5 and some of 11-2 exhibit the classic pattern of autosomal dominant inheritance 
characteristic of MODY, whereas the offspring of 11-3 and 1I-6, as well as III-2 and 1II-9, do 
not. Thus, as brought out and confirmed by molecular genetic studies (see below), it appears 
that heterogeneity of inheritance and type of diabetes appears even in this large pedigree. 
Sibling 11-4 did not have diabetes. None of his 18 offspring of generations III-IV have NIDDM, 
although one granddaughter has classical IDDM. II- 1 had no children. 
I-1 (Fig. 1A) had 3 offspring, 2 of whom had diagnosed diabetes (R branch, Generation II, not 
shown in Figure 1). Among their 10 offspring in generation III, six have or have had diagnosed 
NIDDM. Of twelve tested subjects in Generation IV who are offspring of a diabetic parent, five 
have diabetes. Thus, diabetes is inherited in the autosomal pattern of MODY in the R branch as 
well. None of them are obese. 
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Partial pedigree of the RW family. Offspring of I- 1 belong to the R branch. Offspring 
of I-3 belong to the W branch. Only the offspring of II-5 (A) and II-2 (B) of the W 
branch are shown. All subjects with diabetes were or are non-insulin dependent except 
IV-144 who is insulin-dependent. Diabetic or IGT offspring of II-5 of generations III- 
V (A) and diabetic offspring III-3 and III-8 (B) and their diabetic offspring are genetic 
marker (chromosome 20) positive. In addition, nondiabetic IV-143 (A) and IV-21 (B) 
are genetic marker (GM) positive (+). In generation V, GM+ or negative (-) are 
indicated (A, B). Numbers above male diabetic members (m) or female diabetic 
members ( 0 )  are number in generation and those below are ages at diagnosis. I ,  
Impaired glucose tolerance; Q, normal glucose tolerance; [ ] ,  reported normal and 
untested;<~groups of siblings untested and of unspecified sex with number of 
individualg given; MI, myocardial infarction; PVD, peripheral vascular disease; A, 
amputation; G, gangrene, N, neuropathy, Ang, angina pectoris; R, retinopathy; R-B, 
retinopathy and blindness; NP, nephropathy. All diabetic members of generations I 
and II, along with 111-29 and 1II-30, are deceased. 
MI ~ 
29 R R 
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MODY is usually asymptomatic in younger age groups, although some patients may have 
symptoms, particularly if stressed by an infection. Unless searched out by prospective testing, 
because of a family history of NIDDM in 2 or more generations, in a young person or during a 
pregnancy, a clinical diagnosis of diabetes is frequently not made in many members of such 
families until middle or late adult life. Thus, age of diagnosis cannot be equated to age of onset 
of hyperglycemia. Multigenerational pedigrees of NIDDM, suggestive of MODY, have been 
described in whom not a single affected subject was diagnosed under the age of 29 years but in 
whom molecular genetic studies disclosed a MODY-related mutation (7,8). The impression that 
such mutations may occur in late-onset diabetes may be more apparent than real. Younger 
family members must be screened before typical MODY can be excluded. As demonstrated in 
the RW Pedigree in which MODY is linked to chromosome 20q (see below), it can be 
demonstrated by repeated testing in younger members that there may be a variable rate of 
progression from nondiagnostic (but not normal) glucose tolerance tests to IGT, from IGT to 
diabetic glucose tolerance with normal fasting plasma glucose levels (up to 18 years), and very 
slow or rapid progression to fasting hyperglycemia (0.5 to 27 years). Severity of carbohydrate 
intolerance may fluctuate for many years particularly in patients with mild abnormalities before 
the onset of persistent fasting hyperglycemia. In contrast, other individuals with MODY from 
this pedigree may have fasting hyperglycemia or rapid progression from an early age, even 
though they are asymptomatic. Among nonobese diabetic subjects of the RW Pedigree in 
generations III-V approximately 80% have had fasting hyperglycemia at diagnosis or on follow- 
up. Plasma glucose levels at first detection of fasting hyperglycemia range between 140 to 366 
mg/dl. Approximately 30% had fasting hyperglycemia diagnosed between the ages of 9 and 14 
years or within a 1 to 3 year follow-up. 
Fasting hyperglycemia, even at a young age (9 to 14 years), may be responsive to either diet 
therapy alone, or diet plus oral agents for a few years or decades (3,4,9). With sulfonylurea 
therapy, glucose-induced insulin secretion showed an average increase of 68% in diabetic 
patients who remained responsive to chlorpropamide up to 33 years (9). In most patients, 
however, glucose-induced insulin secretion declines over time (1 to 4% per year). Some patients 
(9-13 years of age at diagnosis) become unresponsive to maximal doses of sulfonylureas after 3 
to 25 years and then have very small or no increases in glucose-induced insulin secretion. They 
require treatment with insulin to normalize fasting hyperglycemia (not insulin-dependent or 
ketotic and islet cell antibody-negative diabetes). At that point, some of these patients have very 
low fasting C-peptide levels, absence of nutrient-stimulated C-peptide levels and an unstable 
type of diabetes resembling that seen in insulin-dependent diabetes (IDDM). Among the known 
diabetic patients from generations III-V of the RW Pedigree approximately 30% have become 
insulin-requiring. Typical microangiopathic and macroangiopathic complications may occur 
similar to those seen in other patients with NIDDM (3,4). 
In contrast to MODY linked to chromosome 20q, as present in the RW pedigree, MODY due to 
mutations in the glucokinase gene on chromosome 7p (see below) is a relatively mild form of 
diabetes with mild fasting hyperglycemia and IGT in the majority that may be recognized by 
biochemical testing at an even younger age (mean 7 + 4 years, minimal age, i year) (10). There 
appears to be little progression of hyperglycemia on follow-up (11,12). Severe fasting 
hyperglycemia and vascular complications appear to be infrequent (Table 1). Thus MODY due 
to glucokinase mutations appears to be a much milder and relatively benign form of 
hyperglycemia, in contrast to the more severe diabetes seen in MODY linked to chromosome 
20q that more closely resembles classical NIDDM. 
Molecular genetics of MODY 
MODY fulfills some of the fundamental requirements for defining the molecular genetic basis of 
any disorder by linkage analysis because of its established autosomal dominant inheritance and 
the availability of large multigenerational kindreds. The RW Pedigree was first used for a search 
of diabetes susceptibility genes by this technique. The initial linkage strategy was to search for 
"candidate genes", that is genes involved in carbohydrate and lipid metabolism. Candidate 
genes excluded as the cause of NIDDM in the RW Pedigree include the insulin, glucagon, islet 
amyloid polypeptide, insulin-like growth factors 1 and 2, insulin receptor, low-density 
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lipoprotein receptor, glucose transporters, apolipoproteins, lipoprotein lipase, hexokinase 1 
genes and the major histocompatibility complex (13). In a subsequent systematic gene mapping 
approach (positional cloning), DNA polymorphisms in the adenosine deaminase gene (ADA) 
and the anonymous locus D20S16 on the long arm of chromosome 20 were found to co- 
segregate with MODY (5,13-17) in members with diabetes of both W and R branches. There are 
no recombinations between these markers and MODY and the lod score presently exceeds 17.0 
at a recombination fraction of 0.00 indicating that the gene responsible for MODY in this family 
is tightly linked to these genes. In the W branch, the descendants of 1I-3 who have NIDDM do 
not carry the at-risk ADA and D20S 16 markers, suggesting that they do not have MODY but 
another form of NIDDM (13-17). In addition, two of five diabetic offspring of 11-2 (III-2 and 
III-9) who are obese and in whom diabetes was diagnosed at the age of 48 and 61 years, 
respectively, do not carry these markers. 
Two subjects (IV-143 and IV-21) in the W branch of the RW pedigree who are over the age of 
25 years are nondiabetic but carry the ADA and D20S16 markers. Thus, these two subjects are 
nonpenetrant (5,13). IV-143 had one glucose tolerance test (GTT) characteristic of IGT and one 
of diabetes at ages 16-17 years but for the following 19 years each GTT has been normal even 
though she has a low insulin response to orally administered glucose. She is very lean, active, 
and has increased sensitivity to insulin during the frequently sampled intravenous glucose 
tolerance test (Bergman's minimal model). During a prolonged low dose glucose infusion, she 
became markedly hyperglycemic. 
The identification of genetic markers for MODY in the RW Pedigree has shown that linkage 
studies of large MODY families can uncover DNA markers for NIDDM (2,13,15). The gene 
responsible for MODY in the RW Pedigree is unknown but is in the region of ADA and D20S 16 
on chromosome 20q. Finding genetic markers is proof at the molecular level that genetic factors 
play an important role in the causation of MODY. DNA typing can identify at risk subjects, i.e., 
genetic screening for prediabetes is possible in the RW Pedigree. MODY is not fully penetrant 
suggesting that environmental factors may also play a role in its development. Identification of 
the MODY gene on chromosome 20 may disclose previously unrecognized mechanisms 
controlling insulin secretion and lead us closer to an understanding of the pathogenesis of 
MODY in this pedigree, with possible application to NIDDM in general. Such studies may lead 
eventually to the prevention, improved treatment, or even a cure for this and other forms of 
NIDDM. 
NIDDM may have different causes even in a single family. Previous clinical characterization 
(also see Insulin secretion below) has suggested heterogeneity of the diabetes in the RW 
Pedigree which was confirmed by the molecular genetic studies. The results of these studies 
support the inclusion of autosomal dominant inheritance in the definition of MODY. The RW 
Pedigree includes two patients with IDDM, one a granddaughter of 11-5 and the other a 
granddaughter of nondiabetic II-4. Because neither of these patients carry the genetic markers 
for MODY, this finding provides evidence that the MODY susceptibility gene does not 
contribute to IDDM in this pedigree (13). Because there is heterogeneity between MODY 
families by hormonal and metabolic characterization (18), it was postulated that additional 
NIDDM susceptibility genes or modifying determinants would be found (13). Indeed, this 
occurred shortly thereafter. 
Tight linkage between MODY and the glucokinase gene on chromosome 7p was found in 
approximately 60% of 32 French MODY families (6,10), in one British family (7,11) and in two 
Japanese families (19,20). Glucokinase is the first rate-limiting enzyme in the metabolism of 
glucose by the pancreatic beta-cell. It causes the phosphorylation of glucose to glucose-6- 
phosphate initiating glycolysis which is essential for insulin secretion. This enzyme has been 
postulated to be the glucose sensing mechanism for insulin secretion (21). Subsequently, a host 
of different mutations (nonsense, missense or deletions) in the glucokinase gene have been found 
in members of  MODY families in which MODY is linked to the glucokinase gene 
(7,10,19,20,22-25). They are believed to cause diabetes by a gene dosage mechanism with a 
modest decrease in glucokinase activity increasing the glucose threshold for insulin secretion. 
Matschinsky has suggested that a 15% decrease in glucokinase activity may raise the threshold 
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of insulin secretion from 5 to 6 mmol (21). Mutations in the glucokinase gene are the most 
common genetic cause of NIDDM identified to date, particularly among MODY pedigrees. In 
one French (6,22) and one British (7) glucokinase-linked MODY pedigrees, there was also 
evidence for genetic heterogeneity in that some diabetic subjects had not inherited the mutant 
glucokinase allele. The RW pedigree is the only large pedigree in which tight linkage of MODY 
to chromosome 20q has been established. Evidence consistent with linkage to chromosome 20q 
has been found in two French (6,10) and one Canadian (D.W. Bowden, E. Colle, unpublished 
results) MODY pedigrees. 
Finally, in addition to the glucokinase gene and the gene on chromosome 20, there must be other 
loci that can cause MODY as MODY pedigrees have been described that show no evidence of 
linkage with glucokinase or markers on chromosome 20 (5,6,10, I 1). 
B-cell function and insulin resistance 
In the RW pedigree, the majority of MODY subjects who were offspring of 11-2 and II-5 have a 
delayed and subnormal insulin secretory response to orally administered glucose, suggesting 
strongly an impairment of B-cell function. In these individuals, impaired B-cell function, 
although moderate in magnitude, appears to the be the major underlying pathogenetic factor for 
abnormal glucose levels. The low insulin secretory response to glucose may occur from 
childhood on and before glucose intolerance appears. It was postulated to be a manifestation of 
the basic genetic defect that leads to diabetes only when additional superimposed environmental 
factors supervene (3,4). A number of environmental determinants superimposed on genetic 
factors may lead to the appearance of IGT or NIDDM in predisposed individuals. In this 
MODY pedigree the important factors appear to be a decreasing physiological insulin 
sensitivity, without the normally associated increase in insulin secretion, as occurs with 
increasing age, growth and increasing body mass, and puberty, as well as a further gain in 
weight without developing obesity when subjects progress from adolescence to young adult age 
(3,4). In addition, as mentioned above, glucose-induced insulin secretion may decline further 
over time (9). Pathological insulin resistance does not appear to be an important contributing 
factor because of normal sensitivity to intravenously administered insulin and because of the 
usually low insulin requirement in insulin-treated diabetic members of the RW Pedigree. In 
contrast, the diabetic but non-MODY offspring of 11-3 and the non-MODY diabetic offspring of 
11-2 are hyperinsulinemic, differentiating them from the offspring of 11-2 and I1-5 who have 
MODY. 
In diabetic MODY patients linked to a mutation in the glucokinase gene, there is evidence of 
decreased insulin secretion by continuous glucose infusion (11,12,26) although the acute insulin 
response to glucose was within normal limits (12,26). A decreased insulin secretory response to 
orally administered glucose has also been reported in glucokinase-linked MODY (20). In 
addition, no evidence of insulin resistance has been reported (12,26) in such patients.. This is in 
contradistinction to patients with other types of NIDDM, most of whom are obese, in whom it 
has been found or postulated that insulin resistance is a more important factor than insulin 
deficiency in the pathogenesis of diabetes (27,28). 
Since chronic hyperglycemia has been reported to be associated with both a decrease of insulin 
sensitivity as well as an impairment of B-cell function, the question of which is the primary 
genetic defect in MODY or NIDDM is very difficult to address in diabetic patients (27). Since 
we now have genetic markers for MODY in the RW Pedigree, we undertook to determine early 
abnormalities of insulin action and of insulin secretion in nondiabetic subjects of the pedigree 
with and without the gene markers to ascertain which of these defects might be primary. Six 
nondiabetic marker-negative and 5 nondiabetic marker-positive members of the RW Pedigree 
were studied, as were 4 mildly diabetic marker-positive family members. Unrelated, young, 
healthy subjects served as comparison groups (29). Insulin action and insulin secretion were 
assessed with a frequently sampled intravenous glucose tolerance test (Bergman Minimal 
Model). Insulin secretion was further assessed during constant low dose glucose infusion by 
deconvolution of plasma C-peptide and by pulse analysis. The nondiabetic marker-positive 
group had normal sensitivity to insulin and unimpaired acute insulin response to intravenous 
Vol. 55, No. 6, 1994 Maturlty-onset Diabetes of the Young 419 
glucose. However, the nondiabetic marker-positive group had decreased mean plasma C-peptide 
concentration and reduced absolute amplitude of insulin secretory ultradian oscillations and 
decreased insulin secretion rate during prolonged glucose infusion (Fig. 2). These responses to 
prolonged glucose infusion were similar to those observed in the diabetic group, who, in 
addition, also had a decreased or absent acute insulin response to intravenous glucose (29). No 
alterations of insulin secretion were observed in the nondiabetic marker-negative family 
members or in the comparison groups. Deranged and deficient insulin secretion, and not insulin 
resistance, appears to be the genetic or primary abnormality that characterizes nondiabetic 
individuals who are predisposed to MODY in the RW pedigree. Prolonged glucose infusion 
studies may reveal qualitative and quantitative defects in insulin secretion not identified by the 
acute insulin response to intravenous glucose. Furthermore, use of the acute insulin response to 
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Quantitative and qualitative differences in insulin secretory defects between MODY with 
glucokinase mutations and MODY with mutation on chromosome 20q have been found by 
studies with acute and more prolonged intravenous infusions of glucose. MODY subjects with 
glucokinase mutations have a first phase insulin response to glucose which is in the normal 
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range (12,26) while mildly diabetic patients with a chromosome 20 mutation have a decreased or 
absent acute insulin response to glucose (29). During graded intravenous glucose infusions, both 
groups of MODY subjects (including nondiabetic marker-positive subjects of the RW pedigree) 
showed a decreased response of the beta-cell to glucose resulting in a downward shift in the 
glucose/insulin secretion rate dose response curve to the right which, in preliminary studies, was 
more severe in RW subjects with a failure of beta cell sensitivity to improve after prolonged 
priming with intravenous glucose (26; M. Byme, S. Fajans, A. Stolz, J. Ortiz, R. Sobel and K. 
Polonsky, Diabetes, June 1994, abstract). Although the specific genetic defect causing MODY 
in the RW pedigree is unknown, the pattern of altered insulin secretion in these subjects suggests 
a unique mechanism of the B-cell dysfunction which may distinguish this form of MODY from 
that due to mutations in the glucokinase gene (Table 1). The greater severity of the insulin 
secretory defect in diabetic and mildly diabetic subjects with mutation in the diabetes 
susceptibility gene on chromosome 20q correlates with a greater severity of hyperglycemia, a 
greater need for insulin therapy and a greater prevalence of vascular complications seen in these 
diabetic subjects than in those with mutations in the glucokinase gene (Table 1). 
TABLE I 
Differences between MODY due to Mutations in the Glucokinase Gene (Chromosome 7p) and 
the Diabetes-Susceptibility Gene on Chromosome 20q 
Fasting hyperglycemia (> 140 mg/dl) 
Postprandial hyperglycemia 
Minimum age at diagnosis 
Need for Insulin Therapy 
Vascular Complications 
AIRglu* 
ISR t during graded IV glucose infusion 
mildly diabetic subjects 
nondiabetic subjects with 
genetic markers 
Glucose priming of ISR 
Glucokinase Gene Chromosome 20q 
0 - ++ 0 - ++++ (approx. 80%) 
0 - ++ ++ - ++++ 
1 year 7 - 9 years 
Uncommon (2%) Common (approx. 30%) 
Rare ++ 
Normal $$ - absent 
$ - $$ $$$ 
Not available $$$ 
Normal (45% increase) Absent 
: ~  o o 
AIRglu - acute lnsuhn response to glucose 
tISR - insulin secretion rate 
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